Excipient for Inhalation

Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) continue as public health concerns. Inhaled drug therapy for TB has substantial...

Introduction Many respiratory pathogens enter the body through the respiratory tract, the lungs and the mucosal immune system are promising...

Pulmonary delivery of antibiotics is an effective strategy in treating bacterial lung infection for cystic fibrosis patients, by achieving high...

Abstract Biopharmaceuticals are labile biomolecules that must be safeguarded to ensure the safety, quality, and efficacy of the product. Batch...

Abstract Drug delivery is essential to provide correct treatments in many ways. The critical points in any drug delivery method...

Abstract Tuberculosis (TB) is an airborne bacterial infection caused by Mycobacterium tuberculosis (M. tb), resulting in approximately 1.3 million deaths in 2022...

Abstract The contributions of fine excipient materials to drug dispersibility from carrier-based dry powder inhalation (DPI) formulations are well acknowledged,...

In recent years, the landscape of pharmaceutical formulations has been witnessing a significant shift towards non-invasive delivery methods. Among these,...

BioHale® is  DFE Pharma´s, high-purity, low-endotoxin product portfolio for the stabilization of biologics. Because stability matters. BioHale® Key promises: Uncompromised...

Introduction Dry powder inhalers (DPI) are gaining popularity in the field of pulmonary treatments due to their numerous advantages. Compared...